Algeta to Participate in Upcoming Investor Conference

Algeta to Participate in Upcoming Investor Conference 
OSLO, NORWAY -- (Marketwired) -- 04/17/13 --  Algeta ASA (OSE:
ALGETA), a company focused on the
development of novel targeted
cancer therapeutics, announces that members of its senior management
and IR teams will participate in the following investor conference: 
Kempen & Co. 6(th) Healthcare/Life Sciences Conference 
Date: 23 April 2013 
Participants: 
Thomas Ramdahl (Chief Technology Officer) 
Renate Birkeli (IR) 
Venue: Amsterdam, The Netherlands 
About Algeta 
Algeta  is a company focused on developing novel targeted therapies
for patients
with   cancer  based  on  its  alpha-pharmaceutical 
platform.  The Company  is headquartered in Oslo, Norway, and has a
US subsidiary, Algeta US, LLC, based in Cambridge,  MA performing
commercial  marketing operations in  the US. Algeta is listed  on the
Oslo Stock Exchange (Ticker: ALGETA). For more information
please
visit www.algeta.com. 
Algeta to Participate in Upcoming Investor Conference: 
http://hugin.info/134655/R/1693399/556601.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Algeta ASA via Thomson Reuters ONE 
[HUG#1693399] 
For further information, please contact: 
Mike Booth / Renate Birkeli
+47 23 00 67 32
Communications & Corporate Affairs
ir@algeta.com 
Media enquiries: 
Mark Swallow
+44 207 638 9571
Citigate Dewe Rogerson
mark.swallow@citigatedr.co.uk 
Knut Ekern
+47 22 04 82 00
Gambit Hill & Knowlton
knut.ekern@hkstrategies.com 
Kari Watson
+1 781 235 3060
MacDougall Biomedical Communications
kwatson@macbiocom.com 
US investor enquiries:
Tricia Swanson
+1 646 378 2953 
The Trout Group
tswanson@troutgroup.com